Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +36.43%
#3 MetaDAO MetaDAO +28.82%
#4 Rain Rain +23.15%
#5 Pons Pons +19.66%
#6 Bedrock Bedrock +18.87%
#7 Prom Prom +18.28%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +17.63%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +17.19%
#10 Ontology Gas Ontology Gas +15.31%
Coin of the day
QuantixAI QuantixAI
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Heidelberg Pharma AG Heidelberg Pharma AG

Heidelberg Pharma AG

HPHA
Classement en actions #20135
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a... Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Prix de l'action
$2.99
Capitalisation boursière
$139.84M
Changement (1 jour)
-0.40%
Changement (1 an)
-41.27%
Pays
DE
Échange Heidelberg Pharma AG (HPHA)

Catégorie

Healthcare
Revenus pour Heidelberg Pharma AG (HPHA)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Heidelberg Pharma AG, le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Heidelberg Pharma AG de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH